Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 23, Issue 21, 2005, Pages 4643-4651

  Schöder, Heiko ^a   Noy, Ariela ^a   Gönen, Mithat ^a   Weng, Lijun ^a   Green, David ^a   Erdi, Yusuf E ^a   Larson, Steven M ^a   Yeung, Henry W D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SCINTISCANNING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 23044469098     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.12.072     Document Type: Article

References (33)

1. Hoh CK, Glaspy J, Rosen P, et al: Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 38:343-348, 1997
2. Carr R, Barrington SF, Madan B, et al: Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 91:3340-3346, 1998
3. Moog F, Bangerter M, Diederichs CG, et al: Extranodal malignant lymphoma: Detection with FDG PET versus CT. Radiology 206:475-481, 1998
4. Jerusalem G, Beguin Y, Fassotte MF, et al: Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429-433, 1999
5. Buchmann I, Reinhardt M, Eisner K, et al: 2-(fluorine-18)fluoro-2-deoxy- D-glucose positron emission tomography in the detection and staging of malignant lymphoma: A bicenter trial. Cancer 91:889-899, 2001
6. Romer W, Hanauske AR, Ziegler S, et al: Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood 91:4464-4471, 1998
7. Spaepen K, Stroobants S, Dupont P, et al: Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 13:1356-1363, 2002
8. Moog F, Bangerter M, Kotzerke J, et al: 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 16:603-609, 1998
9. Schoder H, Meta J, Yap C, et al: Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 42:1139-1143, 2001
10. Jerusalem G, Beguin Y, Najjar F, et al: Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 12:825-830, 2001
11. Elstrom R, Guan L, Baker G, et al: Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101:3875-3876, 2003
12. Rodriguez M, Rehn S, Ahlstrom H, et al: Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 36:1790-1796, 1995
13. Lapela M, Leskinen S, Minn HR, et al: Increased glucose metabolism in untreated non-Hodgkin's lymphoma: A study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 86:3522-3527, 1995
14. Filmont J, Ko Yang F, Yap C, et al: Prediction of malignancy grade using 18FDG PET in Non Hodgkin's lymphoma patients: An urban legend? J Nucl Med 43:79, 2002 (abstr)
15. Rosenberg S: Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. Cancer Treat Rep 61:1023-1027, 1977
16. Erdi YE, Mawlawi O, Larson SM, et al: Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer 80:2505-2509, 1997
17. Harris NL, Jaffe ES, Diebold J, et al: Lymphoma classification-From controversy to consensus: The R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol 11:3-10, 2000 (suppl 1)
18. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
19. Pepe M: The statistical evaluation of medical tests for classification and prediction. Oxford, England Oxford University Press, 2003, pp 66-94
20. Ahuja V, Coleman RE, Herndon J, et al: The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 83:918-924, 1998
21. Wong RJ, Lin DT, Schoder H, et al: Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 20:4199-4208, 2002
22. Eary JF, O'Sullivan F, Powitan Y, et al: Sarcoma tumor FDG uptake measured by PET and patient outcome: A retrospective analysis. Eur J Nucl Med Mol Imaging 29:1149-1154, 2002
23. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al: Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxyglucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases: Leuven Lung Cancer Group. J Clin Oncol 17:3201-3206, 1999
24. Fukunaga T, Okazumi S, Koide Y, et al: Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 39:1002-1007, 1998
25. Oshida M, Uno K, Suzuki M, et al: Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F] -D-glucose. Cancer 82:2227-2234, 1998
26. Nakata B, Chung YS, Nishimura S, et al: 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 79:695-699, 1997
27. Bastion Y, Sebban C, Berger F, et al: Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 15:1587-1594, 1997
28. Leskinen-Kallio S, Ruotsalainen U, Nagren K, et al: Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: A PET study. J Nucl Med 32:1211-1218, 1991
29. Hoffmann M, Kletter K, Becherer A, et al: 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 64:336-340, 2003
30. Blum RH, Seymour JF, Wirth A, et al: Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 4:43-49, 2003
31. Huang SC: Anatomy of SUV: Standardized uptake value. Nucl Med Biol 27:643-646, 2000
32. Yeung HW, Sanches A, Squire OD, et al: Standardized uptake value in pediatric patients: An investigation to determine the optimum measurement parameter. Eur J Nucl Med Mol Imaging 29:61-66, 2002
33. Schoder H, Erdi YE, Chao K, et al: Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients. J Nucl Med 45:559-566, 2004